ublituximab ublituximab ublituximab, sold under the brand name briumvi, is an immunomodulator used for the treatment of multiple sclerosis. it is a cd20-directed cytolytic monoclonal antibody. ublituximabmonoclonal antibodytypewhole antibodysourcechimeric (mouse/human)targetcd20clinical datatrade namesbriumviother namesublituximab-xiiyahfs/drugs.commonographlicense data us dailymed: ublituximab routes ofadministrationintravenousatc codel04aa57 (who) legal statuslegal status us: ℞-only identifierscas number1174014-05-1 ydrugbankdb11850chemspidernoneuniiu59ugk3ipckeggd11243chemical and physical dataformulac6418h9866n1702o2006s48molar mass144504.31 g·mol−1 ny (what is this?) (verify) the most common adverse reactions include infusion reactions, including fever, chills, headache, influenza-like illness, elevated heart rate, nausea, throat irritation, reddening of the skin (erythema) and an anaphylactic (allergic) reaction; infections including serious and fatal bacterial, fungal, and new or reactivated viral infections and reduction in immunoglobulins. it was approved for medical use in the united states in december 2022. medical uses ublituximab is indicated for the treatment of relapsing-remitting, active secondary progressive, and clinically isolated syndrome forms of multiple sclerosis in adults. history researchers demonstrated the efficacy of ublituximab in two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in participants with relapsing forms of multiple sclerosis treated for 96 weeks. participants were randomized to receive either ublituximab or teriflunomide, the active comparator. the primary outcome of both studies was the annualized relapse rate over the treatment period. in both studies, ublituximab significantly lowered the annualized relapse rate compared to teriflunomide. society and culture names ublituximab is the international nonproprietary name (inn).